TIGERMED Joins CRL Consortium to Privatise Frontage; Separation Deal to Unlock ≥RMB0.50 Billion Gain

Bulletin Express11-09

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has signed three definitive agreements that will lead to the privatisation of its Hong Kong-listed subsidiary Frontage Holdings Corporation and the subsequent divestment of Frontage’s overseas laboratory services business.

Key Transaction Structure • Consortium formation: TIGERMED’s Hongkong Tigermed unit, Charles River Laboratories International (CRL) and Frontage founder Dr. Song Li have formed SanRex Ltd. (the “Offeror”), incorporated in the Cayman Islands. Current ownership: CRL 38.27%, Hongkong Tigermed 53.40%, Dr. Li and related trusts 8.35%. • Privatisation proposal: The Offeror will acquire all 2.04 billion Frontage shares via a Cayman scheme of arrangement at HKD 2.370 per share. TIGERMED’s 64.48% stake (1.31 billion shares) will be cancelled; the company itself will receive HKD 535.67 million (≈RMB 461.20 million) in cash for its directly held 226.02 million shares, while Hongkong Tigermed’s 1.09 billion shares will be exchanged for fully-paid Offeror shares. • Option Offer: 79.09 million outstanding Frontage options will be cancelled for a “see-through” cash payment; options where exercise prices exceed the HKD 2.370 offer will be bought for HKD 0.0001 each. • Earn-outs: Former Frontage shareholders and option holders may receive up to USD 50 million for FY-2026 and up to USD 25 million for FY-2027, conditional on revenue and EBITDA margin thresholds for the Target Business.

Separation Transaction Highlights Post-privatisation, TIGERMED will divest Frontage’s non-China laboratory assets to CRL and Dr. Li while retaining Frontage International Limited and all PRC laboratory assets. Key steps include: 1. Asset Restructuring—segregation of target (bioanalysis and DMPK) and non-target assets. 2. Adjustment of Ownership—cash settlements and share redemptions recalibrate equity in the Offeror based on pre-agreed valuations (Target: USD 470.00 million; Non-Target Non-China: USD 84.40 million; Non-Target China: USD 205.50 million). 3. Equity Transfer—Offeror will distribute 100% of Frontage Research (non-China assets) to Frontage ACE (Dr. Li) and 100% of Frontage International Limited (PRC assets) to Hongkong Tigermed; CRL will own 100% of the Offeror and Frontage Holdings thereafter.

Financial Impact on TIGERMED • Immediate cash inflow: HKD 535.67 million from cancellation of Company Scheme Shares, plus additional cash from shareholding adjustments (to be finalised post-closing). • Profit recognition: TIGERMED expects to book a gain of no less than RMB 500.00 million from the divestment of overseas assets and related transactions, after intra-group eliminations. • Proceeds allocation: 60% earmarked for overseas clinical CRO expansion and acquisitions, 20% for general corporate purposes, and up to 20% potentially for future dividends or share buy-backs, subject to board and shareholder approvals.

Regulatory & Shareholder Approvals • Hong Kong: Transactions constitute discloseable and subsidiary-level connected transactions, requiring public disclosure but exempt from shareholder approval under the Listing Rules. • Shenzhen: As anticipated profit exceeds 50% of last year’s audited net profit, the deals require approval at TIGERMED’s extraordinary general meeting (EGM). • EGM commitments: Major shareholders Dr. Ye Xiaoping and Ms. Cao Xiaochun (holding 228.55 million A-shares) have irrevocably undertaken to vote in favour of all resolutions.

Timetable & Conditions The privatisation is contingent on multiple pre-conditions (including TIGERMED shareholder approval and U.S. antitrust clearance) and court, regulatory and shareholder approvals. The scheme long-stop date is 30 June 2027, extendable by mutual agreement.

Post-Transaction Structure On completion of the Separation Transaction, CRL will control 100% of Frontage Holdings and the Offeror, while TIGERMED will deconsolidate Frontage’s overseas assets and liabilities, retaining China-based laboratory operations through Frontage International Limited.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment